Remember....20 Jan 2025 23:00
ImmuPharma PLC, a specialist drug discovery and development company, participated in the JP Morgan Conference and the Biotech Showcase held in San Francisco from January 11 to 16, 2025. The company's delegation included CEO Tim McCarthy, COO Dr. Tim Franklin, and Dr. Sebastien Goudreau, CEO of their R&D subsidiary, ImmuPharma Biotech. These annual events provide biotechnology companies with opportunities to connect with global biopharma companies and investors.
ImmuPharma's attendance aimed to advance discussions on their P140 program, which has attracted significant interest from leading biopharmaceutical companies, particularly in the latter part of 2024. The company is actively pursuing global licensing agreements for this program. This interest aligns with a broader industry trend, as there have been eleven licensing deals exceeding $1 billion for immunology assets between 2023 and late September 2024, indicating a high demand for immunology and autoimmune drug assets among leading biopharma companies.